At a glance
ClinicalIndex Comparison RecordN/ACompleted· 10 enrolled
Drug / intervention
Raltegravirdrug
Likely dose
Raltegravir 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen
In Brief
A clinical study evaluating Raltegravir for HIV and 2 related conditions. Completed, enrolled 10 participants across 1 site.
Detailed Summary
In this study investigators will use a multi-modal imaging approach of MRS and fMRI to comprehensively assess the biological changes in the brain associated with EFV-based regimen (EFV/FTC/TDF), specifically alterations in the brain circuitry, function and local neurochemistry, and their correlation with neuropsychological function.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV, HIV-associated Neurocognitive Disorder, Neurotoxicity
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 2013
Enrollment StartJan 2014
Primary CompletionSep 2016
Study CompletionJan 2017
TodayJul 2026
First PostedNov 7, 2013
Enrollment StartJan 1, 2014
Primary CompletionSep 1, 2016
Study CompletionJan 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 12.7 years ago
Interventions
Raltegravirdrug
Switch from Atripla to Raltegravir 400mg BID + Truvada (FTC/TDF) for total of 8 weeks